Sialyltransferase inhibitors for the treatment of cancer metastasis: Current challenges and future perspectives

Abstract

Potent, cell-permeable, and subtype-selective sialyltransferase inhibitors represent an at-tractive family of substances that can potentially be used for the clinical treatment of cancer metas-tasis. These substances operate by specifically inhibiting sialyltransferase-mediated hypersialyla-tion of cell surface glycoproteins or glycolipids, which then blocks the sialic acid recognition pathway and leads to deterioration of cell motility and invasion. A vast amount of evidence for the in vitro and in vivo effects of sialyltransferase inhibition or knockdown on tumor progression and tumor cell metastasis or colonization has been accumulated over the past decades. In this regard, this review comprehensively discusses the results of studies that have led to the recent discovery and development of sialyltransferase inhibitors, their potential biomedical applications in the treatment of cancer metastasis, and their current limitations and future opportunities.